nach oben

Current Hypertension Reports

Erschienen in:

01.06.2017 | Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Protective Angiotensin Type 2 Receptors in the Brain and Hypertension

verfasst von: Annette D. de Kloet, Ulrike M. Steckelings, Colin Sumners

Erschienen in: Current Hypertension Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this review is to assess the evidence that activation of angiotensin type 2 receptors (AT2R) in the brain can lower blood pressure and possibly constitute an endogenous anti-hypertensive mechanism.

Recent Findings

Recent studies that detail the location of AT2R in the brain, particularly within or near cardiovascular control centers, mesh well with findings from pharmacological and gene transfer studies which demonstrate that activation of central AT2R can influence cardiovascular regulation. Collectively, these studies indicate that selective activation of brain AT2R causes moderate decreases in blood pressure in normal animals and more profound anti-hypertensive effects, along with restoration of baroreflex function, in rodent models of neurogenic hypertension.

Summary

These findings have opened the door to studies that can (i) assess the role of specific AT2R neuron populations in depressing blood pressure, (ii) determine the relevance of such mechanisms, and (iii) investigate interactions between AT2R and depressor angiotensin-(1-7)/Mas mechanisms in the brain.

Ferguson AV. Angiotensinergic regulation of autonomic and neuroendocrine outputs: critical roles for the subfornical organ and paraventricular nucleus. Neuroendocrinology. 2009;89(4):370–6. doi:10.1159/000211202.CrossRefPubMed

Paton JFR, Raizada MK. Neurogenic hypertension. Exp Physiol. 2010;95(5):569–71. doi:10.1113/expphysiol.2009.047282.CrossRefPubMed

Marc Y, Llorens-Cortes C. The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Prog Neurobiol. 2011;95(2):89–103. doi:10.1016/j.pneurobio.2011.06.006.CrossRefPubMed

Leenen FHH. Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension. Am J Hypertens. 2014;27(8):1024–32. doi:10.1093/ajh/hpu066.CrossRefPubMed

Young CN, Davisson RL. Angiotensin-II, the brain, and hypertension: an update. Hypertension. 2015;66(5):920–6. doi:10.1161/HYPERTENSIONAHA.115.03624.CrossRefPubMedPubMedCentral

Unger T, Steckelings UM, Santos RAS dos, editors. In: The protective arm of the renin angiotensin system (RAS). Boston: Academic Press; 2015 [cited 2017 Mar 30]. p. i–ii. Available from: http://www.sciencedirect.com/science/article/pii/B9780128013649099892. doi:10.1016/B978-0-12-801364-9.09989-2

Bader M, Alenina N, Andrade-Navarro MA, Santos RA. MAS and its related G protein-coupled receptors. Mrgprs Pharmacol Rev. 2014;66(4):1080–105.CrossRefPubMed

Gironacci MM, Longo Carbajosa NA, Goldstein J, Cerrato BD. Neuromodulatory role of angiotensin-(1-7) in the central nervous system. Clin Sci. 2013;125(2):57–65. doi:10.1042/CS20120652.CrossRefPubMed

• Santos RA. Angiotensin-(1-7). Hypertension. 2014;63(6):1138–47. doi:10.1161/HYPERTENSIONAHA.113.01274. This is a systematic review of the cardiovascular actions of angiotensin-(1-7) and the role of Mas CrossRefPubMed

10.

McCarthy CA, Widdop RE, Denton KM, Jones ES. Update on the angiotensin AT(2) receptor. Curr Hypertens Rep. 2013;15(1):25–30. doi:10.1007/s11906-012-0321-4.CrossRefPubMed

11.

Matavelli LC, Siragy HM. AT2 receptor activities and pathophysiological implications. J Cardiovasc Pharmacol. 2015;65(3):226–32. doi:10.1097/FJC.0000000000000208.CrossRefPubMedPubMedCentral

12.

Carey RM. Update on angiotensin AT2 receptors. Curr Opin Nephrol Hypertens. 2017;26(2):91–6. doi:10.1097/MNH.0000000000000304.PubMed

13.

Singh KD, Karnik SS. Angiotensin receptors: structure, function, signaling and clinical applications. J Cell Signal. 2016; 1(2). doi:10.4172/jcs.1000111

14.

Bosnyak S, Jones ES, Christopoulos A, Aguilar M-I, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci Lond. 2011;121(7):297–303. doi:10.1042/CS20110036.CrossRefPubMed

15.

Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PML, et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli. Pharmacol Rev. 2015;67(4):754–819. doi:10.1124/pr.114.010454.CrossRefPubMedPubMedCentral

16.

Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Phys. 1991;261(1 Pt 2):R209–16.

17.

Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest. 1991;88(3):921–33. doi:10.1172/JCI115395.CrossRefPubMedPubMedCentral

18.

Cook VI, Grove KL, McMenamin KM, Carter MR, Harding JW, Speth RC. The AT2 angiotensin receptor subtype predominates in the 18 day gestation fetal rat brain. Brain Res. 1991;560(1–2):334–6.CrossRefPubMed

19.

Millan MA, Jacobowitz DM, Aguilera G, Catt KJ, et al. Proc Natl Acad Sci U S A. 1991;88(24):11440–4.CrossRefPubMedPubMedCentral

20.

Lenkei Z, Palkovits M, Corvol P, Llorens-Cortès C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol. 1997;18(4):383–439. doi:10.1006/frne.1997.0155.CrossRefPubMed

21.

Lawrence AJ, Jarrott B. Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Prog Neurobiol. 1996;48(1):21–53.CrossRefPubMed

22.

•• de Kloet AD, Wang L, Ludin JA, Smith JA, Pioquinto DJ, Hiller H, et al. Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system. Brain Struct Funct. 2016;221(2):891–912. doi:10.1007/s00429-014-0943-1. This paper reports the development of a transgenic AT2R reporter mouse, which has enabled the discrete cellular localization of AT2R within and near brain cardiovascular control centers CrossRefPubMed

23.

•• de Kloet AD, Pitra S, Wang L, Hiller H, Pioquinto DJ, Smith JA, et al. Angiotensin type-2 receptors influence the activity of vasopressin neurons in the paraventricular nucleus of the hypothalamus in male mice. Endocrinology. 2016;157(8):3167–80. doi:10.1210/en.2016-1131. This has provided the first documentation of a cardiovascular-related action (secretion of AVP) mediated by AT2R located on a specific set of neurons CrossRefPubMed

24.

Coote JH. A role for the paraventricular nucleus of the hypothalamus in the autonomic control of heart and kidney. Exp Physiol. 2005;90(2):169–73. doi:10.1113/expphysiol.2004.029041.CrossRefPubMed

25.

Kirby RF, Thunhorst RL, Johnson AK. Effects of a non-peptide angiotensin receptor antagonist on drinking and blood pressure responses to centrally administered angiotensins in the rat. Brain Res. 1992;576(2):348–50.CrossRefPubMed

26.

Hogarty DC, Speakman EA, Puig V, Phillips MI, et al. Brain Res. 1992;586(2):289–94.CrossRefPubMed

27.

Yang RH, Jin H, Chen SJ, Wyss JM, Oparil S. Blocking hypothalamic AT1 receptors lowers blood pressure in salt-sensitive rats. Hypertension. 1992;20(6):755–62.CrossRefPubMed

28.

Toney GM, Porter JP. Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats. Neuropharmacology. 1993;32(6):581–9.CrossRefPubMed

29.

Gyurko R, Wielbo D, Phillips MI. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept. 1993;49(2):167–74.CrossRefPubMed

30.

Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995;377(6551):744–7. doi:10.1038/377744a0.CrossRefPubMed

31.

Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377(6551):748–50. doi:10.1038/377748a0.CrossRefPubMed

32.

Gross V, Milia AF, Plehm R, Inagami T, Luft FC. Long-term blood pressure telemetry in AT2 receptor-disrupted mice. J Hypertens. 2000;18(7):955–61.CrossRefPubMed

33.

Li Z, Iwai M, Wu L, Shiuchi T, Jinno T, Cui T-X, et al. Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol. 2003;284(1):H116–21. doi:10.1152/ajpheart.00515.2002.CrossRefPubMed

34.

Matsuura T, Kumagai H, Onimaru H, Kawai A, Iigaya K, Onami T, et al. Electrophysiological properties of rostral ventrolateral medulla neurons in angiotensin II 1a receptor knockout mice. Hypertension. 2005;46(2):349–54. doi:10.1161/01.HYP.0000173421.97463.ac.CrossRefPubMed

35.

Gao L, Wang W, Wang W, Li H, Sumners C, Zucker IH. Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure and urine excretion in normal rats. Hypertension. 2008;51(2):521–7. doi:10.1161/HYPERTENSIONAHA.107.101717.CrossRefPubMed

36.

Gao L, Wang W-Z, Wang W, Zucker IH. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension. 2008;52(4):708–14. doi:10.1161/HYPERTENSIONAHA.108.116228.CrossRefPubMedPubMedCentral

37.

Gao J, Zhang H, Le KD, Chao J, Gao L. Activation of central angiotensin type 2 receptors suppresses norepinephrine excretion and blood pressure in conscious rats. Am J Hypertens. 2011;24(6):724–30. doi:10.1038/ajh.2011.33.CrossRefPubMedPubMedCentral

38.

• Abdulla MH, Johns EJ. The role of brain angiotensin II (type 2) receptors and nitric oxide in the renal sympathoinhibitory response to acute volume expansion in conscious rats. J Hypertens. 2017;35(2):338–47. doi:10.1097/HJH.0000000000001154. This paper provides a strong example of how brain AT2R activation exerts an effect in normal rats—not only under disease conditions CrossRefPubMed

39.

Chao J, Gao J, Parbhu K-JK, Gao L. Angiotensin type 2 receptors in the intermediolateral cell column of the spinal cord: negative regulation of sympathetic nerve activity and blood pressure. Int J Cardiol. 2013;168(4):4046–55. doi:10.1016/j.ijcard.2013.06.051.CrossRefPubMed

40.

• Gao J, Zucker IH, Gao L. Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure. Am J Hypertens. 2014;27(10):1248–56. doi:10.1093/ajh/hpu044. This demonstrated a significant beneficial role for brain AT2R activation under a disease condition - suppression of sympathetic outflow by improving baroreflex sensitivity in rats with heart failure CrossRefPubMedPubMedCentral

41.

• Brouwers S, Smolders I, Wainford RD, Dupont AG. Hypotensive and sympathoinhibitory responses to selective central AT2 receptor stimulation in spontaneously hypertensive rats. Clin Sci. 2015;129(1):81–92. doi:10.1042/CS20140776. This paper was the first to demonstrate the highly significant effect of brain AT2R activation on lowering blood pressure in an animal model of neurogenic hypertension CrossRefPubMedPubMedCentral

42.

• Dai S-Y, Zhang Y-P, Peng W, Shen Y, He J-J. Central infusion of angiotensin II type 2 receptor agonist compound 21 attenuates DOCA/NaCl-induced hypertension in female rats. Oxidative Med Cell Longev. 2016;2016:3981790. doi:10.1155/2016/3981790. This shows that brain AT2R activation lowers blood pressure in female (but not male) DOCA-salt hypertensive rats CrossRef

43.

Dai S-Y, Peng W, Zhang Y-P, Li J-D, Shen Y, Sun X-F. Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats. J Neuroinflammation. 2015;12:47. doi:10.1186/s12974-015-0261-4.CrossRefPubMedPubMedCentral

44.

• Blanch GT, Freiria-Oliveira AH, GFF S, Carrera EJ, Li H, Speth RC, et al. Increased expression of angiotensin II type 2 receptors in the solitary-vagal complex blunts renovascular hypertension. Hypertension. 2014;64(4):777–83. doi:10.1161/HYPERTENSIONAHA.114.03188. This takes a non-pharmacological approach and shows that virus vector-mediated increased expression of AT2R in the NTS significantly decreases renovascular hypertension and restores baroreflex function CrossRefPubMedPubMedCentral

45.

Ruchaya PJ, Speretta GF, Blanch GT, Li H, Sumners C, Menani JV, et al. Overexpression of AT2R in the solitary-vagal complex improves baroreflex in the spontaneously hypertensive rat. Neuropeptides. 2016;60:29–36. doi:10.1016/j.npep.2016.06.006.CrossRefPubMed

46.

Sumners C, de Kloet AD, Krause EG, Unger T, Steckelings UM. Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr Opin Pharmacol. 2015;21:115–21. doi:10.1016/j.coph.2015.01.004.CrossRefPubMedPubMedCentral

47.

Sved AF, Sved JC. Endogenous GABA acts on GABAB receptors in nucleus tractus solitarius to increase blood pressure. Brain Res. 1990;526(2):235–40.CrossRefPubMed

48.

Catelli JM, Sved AF. Enhanced pressor response to GABA in the nucleus tractus solitarii of the spontaneously hypertensive rat. Eur J Pharmacol. 1988;151(2):243–8.CrossRefPubMed

49.

Durgam VR, Vitela M, Mifflin SW. Enhanced gamma-aminobutyric acid-B receptor agonist responses and mRNA within the nucleus of the solitary tract in hypertension. Hypertension. 1999;33(1 Pt 2):530–6.CrossRefPubMed

50.

Han NL, Sim MK. Hypothalamic angiotensin receptor subtypes in normotensive and hypertensive rats. Am J Phys. 1998;275(2 Pt 2):H703–9.

51.

de Kloet AD, Wang L, Ludin JA, Hiller H, Smith JA, Scheuer DA, et al. Abstract 073: hindbrain angiotensin type-2 receptors and hypertension. Hypertension. 2016;68(Suppl 1):A073–3.

52.

Becker LK, Etelvino GM, Walther T, Santos RAS, Campagnole-Santos MJ. Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. Am J Physiol Heart Circ Physiol. 2007;293(3):H1416–24. doi:10.1152/ajpheart.00141.2007.CrossRefPubMed

53.

Karnik SS, Singh KD, Tirupula K, Unal H. Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR review 22. Br J Pharmacol. 2017; [Epub ahead of print]; doi:10.1111/bph.13742.PubMed

54.

Leonhardt J, Villela D, Teichmann A, Münter LM, Mayer MC, Mardahl M, et al. Evidence for heterodimerization and functional interaction of the angiotensin AT2-receptor and the receptor MAS. Hypertension 2017 (in Press).

55.

de Kloet AD, Krause EG, Shi PD, Zubcevic J, Raizada MK, Sumners C. Neuroimmune communication in hypertension and obesity: a new therapeutic angle? Pharmacol Ther. 2013;138(3):428–40. doi:10.1016/j.pharmthera.2013.02.005.CrossRefPubMedPubMedCentral

56.

de Kloet AD, Wang L, Pitra S, Hiller H, Smith JA, Tan Y, et al. A unique “angiotensin-sensitive” neuronal population coordinates neuroendocrine, cardiovascular, and behavioral responses to stress. J Neurosci. 2017;37(13):3478–90. doi:10.1523/JNEUROSCI.3674-16.2017.CrossRefPubMed

57.

Li D-P, Chen S-R, Pan H-L. Angiotensin II stimulates spinally projecting paraventricular neurons through presynaptic disinhibition. J Neurosci. 2003;23(12):5041–9.PubMed

58.

Chen QH, Toney GM. AT(1)-receptor blockade in the hypothalamic PVN reduces central hyperosmolality-induced renal sympathoexcitation. Am J Physiol Regul Integr Comp Physiol. 2001;281(6):R1844–53.PubMed

Titel: Protective Angiotensin Type 2 Receptors in the Brain and Hypertension
verfasst von: Annette D. de Kloet
Ulrike M. Steckelings
Colin Sumners
Publikationsdatum: 01.06.2017
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 6/2017
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-017-0746-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Protective Angiotensin Type 2 Receptors in the Brain and Hypertension